false
0000724004
0000724004
2026-05-27
2026-05-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): MAY 27, 2026
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
|
Colorado
(State or other jurisdiction of
incorporation)
|
0-11740
(Commission File Number)
|
84-0872291
(I.R.S. Employer
Identification No.)
|
|
12100 WEST SIXTH AVENUE,
LAKEWOOD, Colorado
(Address of principal executive offices)
|
|
80228
(Zip Code)
|
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered under Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which
registered
|
| |
|
|
|
|
|
Common Stock, no par value
|
|
MLAB
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
ITEM 2.02
|
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
|
On May 27, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and twelve months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
| |
104
|
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DATE: May 27, 2027
|
|
Mesa Laboratories, Inc.
|
| |
|
(Registrant)
|
| |
|
|
| |
|
|
| |
BY:
|
/s/ John Sakys
|
| |
|
John Sakys
|
| |
|
Chief Financial Officer
|